Cytosorbents Corp (CTSO) Given Somewhat Critical Media Coverage, AlphaOne Reports

Cytosorbents Corp (CTSO) Given Somewhat Critical Media Coverage, AlphaOne Reports

Media stories about Cytosorbents Corp (NASDAQ:CTSO) have been trending somewhat negative on Friday, according to AlphaOne Sentiment Analysis. The research firm, a unit of Accern, identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytosorbents Corp earned a daily sentiment score of -0.03 on AlphaOne’s scale. AlphaOne also assigned news articles about the medical research company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Alpha One’s analysis:

Shares of Cytosorbents Corp (NASDAQ CTSO) traded down 1.23% during midday trading on Friday, hitting $4.00. The stock had a trading volume of 77,556 shares. The firm has a 50 day moving average of $4.56 and a 200-day moving average of $5.19. The company’s market cap is $112.43 million. Cytosorbents Corp has a one year low of $3.95 and a one year high of $6.90.

Cytosorbents Corp (NASDAQ:CTSO) last posted its quarterly earnings data on Monday, May 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.06. The business had revenue of $3.11 million during the quarter, compared to analysts’ expectations of $2.99 million. Cytosorbents Corp had a negative net margin of 120.04% and a negative return on equity of 193.13%. On average, analysts forecast that Cytosorbents Corp will post ($0.28) earnings per share for the current fiscal year.

Several equities analysts recently issued reports on CTSO shares. B. Riley restated a “buy” rating and issued a $11.25 price target on shares of Cytosorbents Corp in a research report on Wednesday, March 1st. Maxim Group set a $10.00 price target on Cytosorbents Corp and gave the company a “buy” rating in a research report on Saturday, March 4th. HC Wainwright boosted their price target on Cytosorbents Corp from $11.50 to $13.00 and gave the company a “buy” rating in a research report on Monday, March 6th. Finally, Aegis restated a “buy” rating on shares of Cytosorbents Corp in a research report on Tuesday, March 7th. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $13.45.

About Cytosorbents Corp

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CTSO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment